Novartis and Proteus sign deal for sensor-based drugs
This article was originally published in Scrip
Executive Summary
Novartis and Proteus Biomedical will collaborate on the development and commercialisation of pharmaceuticals that use Proteus's sensor-based technology in organ transplantation.